{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T04:58:46Z","timestamp":1711169926370},"reference-count":20,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2021,8,31]]},"DOI":"10.5582\/ddt.2021.01006","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T22:07:44Z","timestamp":1630188464000},"page":"218-221","source":"Crossref","is-referenced-by-count":2,"title":["Nivolumab induced hypophysitis in a patient with recurrent non-small cell lung cancer"],"prefix":"10.5582","volume":"15","author":[{"given":"Smile","family":"Kajal","sequence":"first","affiliation":[{"name":"Department of Otolaryngology, All India Institute of Medical Sciences (AIIMS), New Delhi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), New Delhi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anam","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Anatomy, All India Institute of Medical Sciences (AIIMS), New Delhi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pathology, University College of Medical Sciences, New Delhi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Keating GM. Nivolumab: A review in advanced non squamous non-small cell lung cancer. Drugs. 2016; 76:969-978.","DOI":"10.1007\/s40265-016-0589-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, Keegan P, Pazdur R. FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016; 21:634-642.","DOI":"10.1634\/theoncologist.2015-0507"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016; 44:51-60.","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ishikawa M, Oashi K. Case of hypophysitis caused by nivolumab. J Dermatol. 2017; 44:109-110.","DOI":"10.1111\/1346-8138.13437"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Garon-Czmil J, Petitpain N, Rouby F, Sassier M, Babai S, Y\u00e9l\u00e9h\u00e9-Okouma M, Weryha G, Klein M, Gillet P. Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French pharmacovigilance database. Sci Rep. 2019; 9:19419.","DOI":"10.1038\/s41598-019-56026-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Faje A, Reynolds K, Zubiri L, Lawrence D, Cohen JV, Sullivan RJ, Nachtigall L, Tritos N. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019; 181:211-219.","DOI":"10.1530\/EJE-19-0238"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Joshi MN, Whitelaw BC, Palomar MT, Wu Y, Carroll PV. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: Clinical review. Clin Endocrinol. 2016; 85:331-339.","DOI":"10.1111\/cen.13063"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Howlett TA, Levy MJ, Robertson IJ. How reliably can autoimmune hypophysitis be diagnosed without pituitary biopsy. Clin Endocrinol (Oxf). 2010; 73:18-21.","DOI":"10.1111\/j.1365-2265.2009.03765.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Faje A. Hypophysitis: Evaluation and management. Clin Diabetes Endocrinol. 2016; 2:15.","DOI":"10.1186\/s40842-016-0034-8"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016; 19:82-92.","DOI":"10.1007\/s11102-015-0671-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L. Ipilimumab induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014; 99:4078-4085.","DOI":"10.1210\/jc.2014-2306"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Chodakiewitz Y, Brown S, Boxerman JL, Brody JM, Rogg JM. Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis. Clin Neurol Neurosurg. 2014; 125:125-130.","DOI":"10.1016\/j.clineuro.2014.06.011"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lam T, Chan MM, Sweeting AN, De Sousa SM, Clements A, Carlino MS, Long GV, Tonks K, Chua E, Kefford RF, Chipps DR. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series. Intern Med J. 2015; 45:1066-1073.","DOI":"10.1111\/imj.12819"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014; 21:371-381.","DOI":"10.1530\/ERC-13-0499"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gambale E, Tinari C, Carella C, Paolo AD, Tursi MD. Immunotherapy and hypophysitis in the clinical practice: A case report. J Clin Case Rep. 2016; 6:861.","DOI":"10.4172\/2165-7920.1000861"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metabol. 2013; 98:1361-1375.","DOI":"10.1210\/jc.2012-4075"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Torino F, Barnabei A, Paragliola RM, Marchetti P, Salvatori R, Corsello SM. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. European J Endocrinol. 2013; 169:R153-R164.","DOI":"10.1530\/EJE-13-0434"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Topalian SL, Sznol M, McDermott DF, <i>et al<\/i>. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014; 32:1020-1030.","DOI":"10.1200\/JCO.2013.53.0105"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Robert C, Ribas A, Wolchok JD, <i>et al<\/i>. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose comparison cohort of a phase 1 trial. Lancet. 2014; 384:1109-1117.","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Nguyen H, Shah K, Waguespack SG, <i>et al<\/i>. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocr Relat Cancer. 2021; 28:419-431.","DOI":"10.1530\/ERC-20-0513"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/15\/4\/15_2021.01006\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T03:53:25Z","timestamp":1632542005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/15\/4\/15_2021.01006\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2021.01006","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"article-number":"2021.01006"}}